EORTC participates in transatlantic intergroup trial on rare tumors
19 Jan 2015
The chance of relapse or recurrence for patients with early-stage, high grade uterine leiomyosarcoma is approximately 50% to 70%, and recurrences can be distant and / or local. Currently, for women with completely resected high grade leiomyosarcoma that is confined to the uterus, the standard treatment is observation. So far, no prospective, randomized clinical trial has shown any interventions that are capable of improving recurrence-free or overall survival in these patients.
Dr. Petronella Ottevanger of the Radboud University Nijmegen Medical Centre, The Netherlands, Secretary of the EORTC Gynecological Cancer Group, and Coordinator of this study says, “The killing potential of this disease deserves a proper randomized investigation of the potential benefits of adjuvant chemotherapy.”
The phase III randomized EORTC 55116 – 62114 trial has now opened to answer the question of whether adjuvant chemotherapy might improve survival for women with this disease. Following complete resection of the leiomyosarcoma, women in the chemotherapy arm of this trial will receive gemcitabine plus docetaxel followed by doxorubicin. Patients in the control arm will be assigned to observation, the standard practice.
The primary objective of this trial is to see if overall survival of patients receiving adjuvant chemotherapy is superior to that of patients receiving standard practice. Secondary objectives include seeing whether adjuvant chemotherapy improves recurrence-free survival as well as exploring the impact of potential predictors of recurrence or death (e.g. age, size of the tumor, absence or presence of cervical involvement, and mitotic rate).
Dr. Anders Krarup-Hansen of the Herlev Hospital at the University Copenhagen, Denmark, and Principal Investigator for the EORTC Soft Tissue and Bone Sarcoma Group in this study says, “This important problem will now be solved in a large scale cooperative phase III trial, I do hope this kind of set up will be a model for future trials in sarcomas.”
EORTC trial 55116 – 62114 plans to accrue 216 patients and will be conducted in multiple sites located in eleven countries: Belgium, Canada, Denmark, France, Germany, Italy, Norway, Spain, The Netherlands, the United States of America, and the United Kingdom. This intergroup trial is led by the Gynecological Cancer Group USA in collaboration with the EORTC Gynecological Cancer and Soft Tissue and Bone Sarcoma Groups and NCRN (Cancer Research UK). Uterine leiomyosarcoma is a rare cancer, and this study is part of International Rare Cancer Initiative (IRCI). This trial is supported by the United States National Cancer Institute.
For more information concerning EORTC trial 55116 – 62114 please contact: www.eortc.org/contact
John Bean, PhD
EORTC, Medical Science Writer
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024